However, accumulating evidence has challenged this view by showing that PRL is also immunosuppressive [12–14], and that hyperprolactinemia occurring during pregnancy and lactation [15, 16] or induced pharmacologically by the dopamine D2 receptor antagonist haloperidol [17], is associated with a reduction in the severity and risk of RA. This evidence concerns the gene PRL and hyperprolactinemia.